X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (220) 220
male (157) 157
middle aged (156) 156
female (155) 155
index medicus (153) 153
aged (134) 134
adult (123) 123
life sciences (118) 118
oncology (115) 115
hematology (113) 113
cancer (105) 105
aged, 80 and over (81) 81
antineoplastic combined chemotherapy protocols - therapeutic use (79) 79
rituximab (69) 69
chemotherapy (67) 67
treatment outcome (65) 65
lymphomas (60) 60
non-hodgkins-lymphoma (59) 59
prognosis (58) 58
[ sdv.can ] life sciences [q-bio]/cancer (56) 56
lymphoma (46) 46
survival (43) 43
[sdv.can]life sciences [q-bio]/cancer (42) 42
disease-free survival (42) 42
lymphoma, large b-cell, diffuse - drug therapy (41) 41
adolescent (37) 37
elderly-patients (36) 36
hemic and lymphatic diseases (36) 36
survival analysis (36) 36
cyclophosphamide - administration & dosage (35) 35
b-cell lymphoma (33) 33
doxorubicin - administration & dosage (32) 32
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
cyclophosphamide (30) 30
prednisone - administration & dosage (30) 30
retrospective studies (30) 30
therapy (29) 29
young adult (29) 29
care and treatment (28) 28
antineoplastic combined chemotherapy protocols - administration & dosage (27) 27
lymphoma, large b-cell, diffuse - genetics (27) 27
lymphoma, large b-cell, diffuse - mortality (27) 27
expression (26) 26
vincristine - administration & dosage (26) 26
neoplasm staging (25) 25
doxorubicin (24) 24
follow-up studies (24) 24
kaplan-meier estimate (24) 24
mutation (23) 23
recurrence (23) 23
survival rate (23) 23
transplantation (23) 23
combined modality therapy (22) 22
lymphoma, large b-cell, diffuse - pathology (22) 22
trial (22) 22
antineoplastic agents - therapeutic use (21) 21
doxorubicin - therapeutic use (21) 21
follicular lymphoma (21) 21
leukemia (21) 21
prospective studies (21) 21
vincristine (21) 21
antibodies, monoclonal, murine-derived (20) 20
antibodies, monoclonal, murine-derived - therapeutic use (20) 20
cyclophosphamide - therapeutic use (20) 20
lymphoma, follicular - drug therapy (20) 20
patients (19) 19
prednisone - therapeutic use (19) 19
clinical trials (18) 18
multivariate analysis (18) 18
prednisone (18) 18
risk factors (18) 18
time factors (18) 18
hematology, oncology and palliative medicine (17) 17
immune system diseases (17) 17
proportional hazards models (17) 17
vincristine - therapeutic use (17) 17
[ sdv ] life sciences [q-bio] (16) 16
abridged index medicus (16) 16
analysis (16) 16
diffuse large b-cell lymphoma (16) 16
disease (16) 16
france (16) 16
genetics & heredity (16) 16
antibodies, monoclonal, murine-derived - administration & dosage (15) 15
drug administration schedule (15) 15
health aspects (15) 15
stem cells (15) 15
[sdv]life sciences [q-bio] (14) 14
hematopoietic stem cell transplantation (14) 14
immunology (14) 14
remission induction (14) 14
transplantation, autologous (14) 14
antibodies, monoclonal - administration & dosage (13) 13
antibodies, monoclonal - therapeutic use (13) 13
cytarabine - administration & dosage (13) 13
doxorubicin - adverse effects (13) 13
lymphocytes b (13) 13
lymphoma, non-hodgkin - drug therapy (13) 13
non-hodgkin-lymphoma (13) 13
positron-emission-tomography (13) 13
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
UofT at Mississauga - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Victoria University E.J. Pratt - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Life Sciences
Journal Article
by Bougouin, Wulfran and Marijon, Eloi and Planquette, Benjamin and Karam, Nicole and Dumas, Florence and Celermajer, David and Jost, Daniel and Lamhaut, Lionel and Beganton, Frankie and Cariou, Alain and Meyer, Guy and Jouven, Xavier and Bureau, Côme and Charpentier, Julien and Salem, Omar Ben Hadj and Guillemet, Lucie and Arnaout, Michel and Ferre, Alexis and Geri, Guillaume and Mongardon, Nicolas and Pène, Frédéric and Chiche, Jean-Daniel and Mira, Jean-Paul and Labro, Guylaine and Belon, François and Luu, Vinh-Phuc and Chenet, Julien and Besch, Guillaume and Puyraveau, Marc and Piton, Gaël and Capellier, Gilles and Martin, Maëlle and Lascarrou, Jean-Baptiste and Le Thuaut, Aurélie and Lacherade, Jean-Claude and Martin-Lefèvre, Laurent and Fiancette, Maud and Vinatier, Isabelle and Lebert, Christine and Bachoumas, Konstantinos and Yehia, Aihem and Henry-Laguarrigue, Matthieu and Colin, Gwenhaël and Reignier, Jean and Privat, Elodie and Escutnaire, Joséphine and Dumont, Cyrielle and Baert, Valentine and Vilhelm, Christian and Hubert, Hervé and Robert-Edan, Vincent and Lakhal, Karim and Quartin, Andrew and Hobbs, Brian and Cely, Cynthia and Bell, Cynthia and Pham, Tai and Schein, Roland and Geng, Yimin and Ng, Chaan and Ehrmann, Stephan and Gandonnière, Charlotte Salmon and Boisramé-Helms, Julie and Le Tilly, Olivier and De Bretagne, Isabelle Benz and Mercier, Emmanuelle and Mankikian, Julie and Bretagnol, Anne and Meziani, Ferhat and Halimi, Jean Michel and Le Guellec, Chantal Barin and Gaudry, Stéphane and Hajage, David and Tubach, Florence and Pons, Bertrand and Boulet, Eric and Boyer, Alexandre and Chevrel, Guillaume and Lerolle, Nicolas and Carpentier, Dorothée and de Prost, Nicolas and Lautrette, Alexandre and Mayaux, Julien and Nseir, Saad and Ricard, Jean-Damien and Dreyfuss, Didier and Robert, René and Garzotto, Franscesco and Kipnis, Eric and Tetta, Ciro and Ronco, Claudio and Schnell, David and Aurelie, Bourmaud and Reynaud, Marie and Clec’h, Christophe and Benyamina, Mourad and Vincent, François and Mariat, Christophe and Bornstain, Caroline and Rouleau, Stephane and ... and ENCEPHALITICA Study Group and GFRUP RMEF and for the EurêClark Study Group and REVA ECMOnet and REA-RAISIN Study Group and Sudden Death Expertise Center and for the HYPER2S Investigators and REVA Research Network and for the Purpura Fulminans Study Group and DO-RE-MI-FA Group and AKIKI Study Group and Groupe Communication et Simulation en Pédiatrie
Annals of Intensive Care, ISSN 2110-5820, 1/2017, Volume 7, Issue S1, pp. 1 - 104
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 76 - 86
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1136 - 1143
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1066 - 1073
Journal Article
American Journal of Hematology, ISSN 0361-8609, 02/2016, Volume 91, Issue 2, pp. 179 - 184
Journal Article